Overview
Aliquot reports the evidence type and pharmacokinetic context without turning study findings into a benefit claim or dosing recommendation.
A human study can support pharmacokinetic context but does not establish approval, effectiveness for personal use, or an appropriate regimen.
Human pharmacokinetic context
7 days
Peer-reviewed human study · subcutaneous injection
Half-life is descriptive population context, not a dosing interval, a prediction of an individual's response, or a recommendation. Route-mismatched and uncited estimates are withheld.
Limitations
- A small human study is not an approval record or a personal-use recommendation.
- Study estimates do not predict an individual's response.
Related calculation tools
Aliquot's browser-only tools transform values you already have. They do not select a compound, suggest an amount, provide presets, or store your entries.
Sources
- Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults Route-specific human pharmacokinetic context.
- Drugs@FDA: FDA-approved drugs Regulatory database consulted; no approval conclusion is asserted.
- Aliquot compound library methodology Editorial scope and withholding rules.